Senesco Logo
Home About Us News and Media Our Technologies Clinical Development Commercialization Investor Relations Contact Us
COMMERCIALIZATION
 
       
  > Therapeutics > Agriculture
  Therapeutics
Senesco’s eIF5A-based technology platform has proven relevant to human therapeutic applications. The eIF5A gene is highly conserved among eukaryotes and we have demonstrated ourselves and with collaborators that it functions similarly from plants to people. Our proprietary advantage and considerable know-how enable us to develop a series of innovative therapeutic candidates for treatment of multiple conditions, especially in cancer and inflammation.

Our current focus is on cancer, and specifically on multiple myeloma (MM) and other B-cell cancers including mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL) and diffuse large B-cell lymphoma (DLBCL). Our first product candidate, SNS01-T has been shown to inhibit the growth and even shrink tumors in animal models of human B-cell cancers, including multiple myeloma, mantle cell lymphomia and diffuse large b-cell lymphoma.

  Disclaimer
facebook twitter youtube google+ linkedin